A Rational Approach for Creating Peptides Mimicking Antibody Binding

Area of Science:

• Biotechnology
• Molecular Biology
• Drug Discovery

Background:

• Antibodies are crucial for targeted therapies but can be large and expensive.
• Developing smaller, potent peptide mimics of antibody binding is highly desirable.
• Epidermal Growth Factor Receptor (EGFR) is a key target in various cancers.

Purpose of the Study:

• To present a novel method for designing peptides that mimic antibody binding to EGFR.
• To synthesize and characterize these designed peptides for specificity, affinity, and functional activity.
• To evaluate the efficacy of peptide-drug conjugates in targeting EGFR-overexpressing cancer cells.

Main Methods:

• Utilized the Knob-Socket model to map the Cetuximab-EGFR interaction surface.
• Designed EGFR-binding peptides based on geometric and probabilistic analysis of mapped knob-socket pairs.
• Synthesized peptides, characterized binding kinetics (K_D), cellular uptake, cytotoxicity of peptide-drug conjugates (Monomethyl Auristatin E - MMAE), and phosphorylation inhibition.

Main Results:

• Designed peptides demonstrated specific binding and internalization into EGFR-overexpressing cells (3-4 fold higher uptake).
• The peptide Pep11 exhibited high affinity for EGFR with a K_D of 252 nM.
• Monomethyl Auristatin E-EGFR-Pep11 conjugate showed >2000-fold higher cytotoxicity against EGFR-overexpressing cell lines (A431, MDA MB 468) compared to control cells, and >90-fold reduced toxicity compared to MMAE alone against non-overexpressing cells.

Conclusions:

• A rational peptide design method based on the knob-socket model was successfully developed.
• This method effectively mimics antigen-antibody interactions, yielding peptides with antibody-like specificity, affinity, and functionality.
• The designed peptides hold promise for targeted drug delivery systems against EGFR-driven cancers.